NASDAQ · COLL

Collegium Pharmaceutical, Inc.

$35.52 +$0.32 (+0.91%) 1D After hours
Charting by TradingView

Key Metrics

$1.14B
Market cap
15.23×
P/E · TTM
$796.33M
Revenue · TTM
$74.95M
Net income
EPS · TTM $2.28
Dividend yield —
Free cash flow $329.83M
Beta · 1Y 0.32
EBITDA · TTM $111.79M
Gross margin 60.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 2
    From its Feb 4 high, the share price fell 37%.

    Peak close $48.18 on Feb 4; trough close $30.48 on Jun 2. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -37%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$1.14B
Enterprise value—
Shares outstanding32.4M
52-wk range$29.19 – $50.79
Avg volume · 20D383.1K
Net cash —
Book value / share$9.51
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Collegium Pharmaceutical, Inc.
IPO dateMay 7, 2015
Employees423

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E15.23
P/S1.43
P/FCF3.46
EV/EBITDA—
EV/Sales—
Graham №$22.10

Profitability

Gross 60.7%
Operating 13.6%
Net 9.4%
FCF 41.4%
ROE / ROIC 27.7% · -68.6%

Financial Health

Current ratio1.71
Quick ratio1.62
Debt / equity—
Debt / EBITDA —
Net cash —
Working capital$310.70M

Cash Flow · TTM

Operating CF $331.04M
Capex −$1.21M
Free cash flow $329.83M
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

5 / 9
Middling fundamentals · 5 of 9 signals passing

Altman Z-Score

1.4
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$22.10 vs $35.52
Trades 1.6× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings